RAPID DIGITAL INNOVATION
SYNAPSE - BOEHRINGER INGELHEIM’S INNOVATION PROGRAM BY BI X
This program is designed to foster partnerships between innovative startups, scaleups and more established companies and Boehringer Ingelheim, with the aim of disrupting the digital health landscape.
After a successful launch in France, BI X is now expanding the program internationally.
RAPID DIGITAL INNOVATION
SYNAPSE - BOEHRINGER INGELHEIM’S INNOVATION PROGRAM BY BI X
This program is designed to foster partnerships between innovative startups, scaleups and more established companies and Boehringer Ingelheim, with the aim of disrupting the digital health landscape.
After a successful launch in France, BI X is now expanding the program internationally.
WHAT IS SYNAPSE?
Synapse is a platform for companies to collaborate with Boehringer Ingelheim on pilot projects. It offers the opportunity to establish connections with various business units and functions and to work on meaningful topics, facilitated by BI X.
SELECTED INNOVATION PARTNER
We are proud to announce that we have selected our partner for this year's pilot project. The selected company, Inato, has created a global clinical trial marketplace that brings research to patients where they live, facilitating simple and efficient participation by doctors and patients. We are now in the pilot phase and look forward to working with Inato.
After an initial success in the healthcare field, we realized that this was an area that the team really liked and where our automated inspection technologies made a lot of sense. So, we looked for the best way to develop in the Pharma industry and Synapse is THE reference program in this field. And the fact that the program combines Industry 4.0, co-development, and health, for us it was a winning trio that would allow us to develop. So, we applied.
Rodolph Vogt, CEO, M-Cador
WHAT IS SYNAPSE?
Synapse is a platform for companies to collaborate with Boehringer Ingelheim on pilot projects. It offers the opportunity to establish connections with various business units and functions and to work on meaningful topics, facilitated by BI X.
SELECTED INNOVATION PARTNER
We are proud to announce that we have selected our partner for this year's pilot project. The selected company, Inato, has created a global clinical trial marketplace that brings research to patients where they live, facilitating simple and efficient participation by doctors and patients. We are now in the pilot phase and look forward to working with Inato.
After an initial success in the healthcare field, we realized that this was an area that the team really liked and where our automated inspection technologies made a lot of sense. So, we looked for the best way to develop in the Pharma industry and Synapse is THE reference program in this field. And the fact that the program combines Industry 4.0, co-development, and health, for us it was a winning trio that would allow us to develop. So, we applied.
Rodolph Vogt, CEO, M-Cador
BENEFIT FROM A GLOBAL PLAYER
Boehringer Ingelheim is an international company with 52,000 employees in more than 130 countries.
At BI X, we are experts in digital health innovation, having successfully developed and launched numerous digital health solutions across various markets. By joining our program, you will gain access to Boehringer's extensive network of experts, contacts, and mentors, both internally and externally.
Synapse provides exclusive access to funding for testing and deploying projects, fostering an environment for your ideas to thrive and succeed.
BENEFIT FROM A GLOBAL PLAYER
Boehringer Ingelheim is an international company with 52,000 employees in more than 130 countries.
At BI X, we are experts in digital health innovation, having successfully developed and launched numerous digital health solutions across various markets. By joining our program, you will gain access to Boehringer's extensive network of experts, contacts, and mentors, both internally and externally.
Synapse provides exclusive access to funding for testing and deploying projects, fostering an environment for your ideas to thrive and succeed.
All Applications Have Been Successfully Received
The agenda for the program is outlined below.
Pilot Scoping Phase: May-June 2024
Startups pre-selected for the program will work with BI X and Boehringer Ingelheim experts to define the scope of their collaboration.
Selection Days: July 3-4 on-site in Ingelheim, Germany (attendance is mandatory for selected companies)
Selected companies will finalize and present their collaboration proposals to Boehringer Ingelheim decision makers for a decision to proceed to the pilot phase and for feedback.
Pilot phase: Fall 2024
Selected companies will conduct the planned pilot project together with Boehringer Ingelheim to explore and validate the scoped use case.
WHAT ELSE DO YOU NEED TO KNOW?
The accelerator program is free for all start-ups. All Boehringer Ingelheim / BI X requires is that start-ups maintain an open, transparent and constructive working relationship. The new program will start mid-2025.
Contact us: If you have any questions, please contact Eero Toppinen and Aino Heiska who are driving the operations of the program.
WHAT ELSE DO YOU NEED TO KNOW?
The accelerator program is free for all start-ups. All Boehringer Ingelheim / BI X requires is that start-ups maintain an open, transparent and constructive working relationship. The new program will start mid-2025.
Contact us: If you have any questions, please contact Eero Toppinen and Aino Heiska who are driving the operations of the program.
